SWHR joined 25 organizations in urging the Food and Drug Administration (FDA) and National Institutes of Health (NIH) to include […]
SWHR provided Representative Diana DeGette (D-CO) and Representative Fred Upton (R-MI) with initial feedback today in response to their recent […]
SWHR and other members of the Coalition to Advance Maternal Therapeutics (CAMT) urged the National Institutes of Health (NIH) and […]
The Duke-Margolis Center for Health Policy is convening a public meeting to discuss the need for clinical research in pregnant women as well as scientific and ethical considerations for the inclusion of this complex population in clinical trials.
SWHR is thrilled with the news that women accounted for 72% of all clinical trial participants for FDA-approved new drugs in 2019.
Women’s Health Research Day celebrates the day that NIH’s policy requiring inclusion of sex as a biological variable in research took effect.
SWHR and FasterCures, a center of the Milken Institute, released a report outlining the positive changes for women’s health research from the 21st Century Cures Act.
In a letter to the White House Office of Science and Technology Policy (OSTP), SWHR recommended the government prioritize biotechnology […]
While NIH policies intend to correct imbalances in studying females, one researcher argues that the new movement on including sex as a biological variable has backfired in implementation.
In a letter to the Secretary of Health and Human Services, SWHR expressed its concerns about the future status of […]